CTOs on the Move

Organic Potash Corporation

www.organicpotash.com

 
Through its proprietary patented technology, Organic Potash Corporation produces 99%+ pure potassium carbonate (potash) from the ash of agricultural waste, in particular, cocoa husks. The purity of the company’s potassium carbonate will allow Organic Potash Corporation to target multiple industries including the Agricultural and Pharmaceutical industry. Organic Potash Corporation is headquartered in Toronto, Ontario and its shares trade on the Canadian National Stock Exchange under the trading symbol “OPC”.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Pharmacyclics

Pharmacyclics, an AbbVie company, is a biopharmaceutical company located in Sunnyvale, CA employing more than 900 people. We focus on developing and commercializing innovative small-molecule therapies for the treatment of certain cancers and immune-mediated diseases.

Kaup Pharmacy

Kaup Pharmacy is a Fort Recovery, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HepQuant

HepQuant is a Aurora, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Low T Center

Low T Center, mens health clinic, offers treatment for low t levels with testosterone replacement therapy, (hormone replacement), and sleep apnea .

SAB Biotherapeutics

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine™ herds that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. SAB`s versatile DiversitAb™ platform is appliable to a wide range of serious unmet needs in human diseases. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB is currently advancing multiple clinical programs and has a number of collaborations with the US government and global pharmaceutical companies.